Vyome Therapeutics, a Princeton-based company developing therapies for inflammatory diseases, announced on Tuesday it has appointed Craig Tooman as chief operating officer and chief financial officer.
Tooman has more than 25 years of experience the biotechnology and pharmaceutical industries.
“It is with great pleasure and excitement that we welcome Craig to the Vyome team,” Venkat Nelabhotla, CEO and president of Vyome Therapeutics, said. “Craig is a seasoned industry executive with many years of experience as a biopharma CFO, during which he created and built companies and led the raise of over $5.5 billion in capital. This wealth of experience building life sciences companies and leading successful financing initiatives, including IPOs and mergers and acquisitions, will prove to be invaluable as Vyome continues to advance its pipeline.”
Prior to Vyome, Tooman was the CEO of pet therapeutic company Aratana Therapeutics. During his six years there, he held the roles of chief financial officer and treasurer. Before that, he was the founder and CEO of oncology company Avanzar Medical Inc. He also was the chief financial officer at Ikaria Inc. and Enzon Pharmaceuticals and spent time at Sigma Tau, Genzyme, Pharmacia and Stockbourne LLC.
“Vyome’s locally-acting, next generation drug candidates represent an exciting and promising new approach to treating inflammation-driven diseases of unmet need. I’m thrilled to have the opportunity to work alongside the exceptional leadership team at Vyome, as well as help shape the company’s strategy as it continues improving current standards of care for inflammatory diseases and VB-1953 advances in the clinic,” Tooman said.
